Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies 

 

Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
March 31, 2015 – (Ocata) – Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration (AMD) and Stargardt’s Macular Degeneration (SMD).

 

 

Posted on 31-Mar-15 by Berry, Cassie
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: